Boxed warning about potential QTc prolongation associated with antipsychotic mesoridazine is added to labeling, and product is restricted to second-line status. The change is similar to a July relabeling for Novartis' chemically-related product Mellaril (1"The Pink Sheet" July 17, p. 12). Mesoridazine is a Mellaril (thioridazine) metabolite
You may also be interested in...
Novartis Mellaril's black box warning that thioridazine causes QTc prolongation will shift it to a second-line anti-psychotic therapy.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials